Approved indications and other possible utilizations of anti-TNFa biologic drugs

Main Article Content

W. Grassi *
C. Montecucco
(*) Corresponding Author:
W. Grassi | office@pagepress.org

Abstract

The article describes the EMEA approved indications of TNFa antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFa antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)

1 2 3 > >>